No clinical utility of **KRAS** variant rs61764370 for ovarian or breast cancer

*A full list of authors and affiliations appears at the end of the article.*

**Abstract**

**Objective**—Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a **KRAS** 3′ UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370.

**Methods**—Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of **BRCA1** and **BRCA2** (14,765 **BRCA1** and 7904 **BRCA2** mutation carriers).

**Results**—We found no association with risk of ovarian cancer (OR= 0.99, 95% CI 0.94–1.04, p = 0.74) or breast cancer (OR = 0.98, 95% CI 0.94–1.01, p = 0.19) and results were consistent among mutation carriers (**BRCA1**, ovarian cancer HR = 1.09, 95% CI 0.97–1.23, p = 0.14, breast cancer HR = 1.04, 95% CI 0.97–1.12, p = 0.27; **BRCA2**, ovarian cancer HR = 0.89, 95% CI 0.71–1.13, p = 0.34, breast cancer HR = 1.06, 95% CI 0.94–1.19, p = 0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR = 0.94, 95% CI 0.83–1.07, p = 0.38), breast cancer (HR = 0.96, 95% CI 0.87–1.06, p = 0.38), and all other previously-reported associations.

**Conclusions**—rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.

**Keywords**

**KRAS** variant; Breast cancer; Ovarian cancer; Genetic association; Clinical outcome

---

*Corresponding author at: Duke Cancer Institute, Duke University Medical Center, Box 3079, Durham, NC 27710, USA. Tel.: +1 919 684 4943; fax: +1 919 684 8719. berch001@mc.duke.edu (A. Berchuck).

1 Equal contributions.

**Conflict of interest statement**

There are no conflicts of interest to disclose.

Antoinette Hollestelle and Ellen L. Goode had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.ygyno.2015.04.034](http://dx.doi.org/10.1016/j.ygyno.2015.04.034).
1. Introduction

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that negatively regulate gene expression by binding partially complementary sites in the 3' untranslated regions (UTRs) of their target mRNAs. In this way, miRNAs control many cancer-related biological pathways involved in cell proliferation, differentiation, and apoptosis [1]. To date, several inherited variants in microRNAs or miRNA target sites have been reported to confer increased cancer risks [2]. One such variant is located in the 3' UTR of the KRAS gene (rs61764370 T > G) for which the rarer G allele has been reported to confer an increased risk of ovarian, breast, and lung cancer [3–7] as well as endometriosis [8], although not consistently [9–11].

For ovarian cancer, the rs61764370 G allele was also reported to be associated with increased risk (320 cases, 328 controls). Further increased risks were observed among 23 BRCA1 mutation carriers and 31 women with familial ovarian cancer, but without BRCA1 or BRCA2 mutations [3]. In contrast, no association with ovarian cancer risk was seen in another, much larger study, based on 8669 cases, 10,012 controls, and 2682 BRCA1 mutation carriers [9]. One criticism on the latter study was that some of the genotype data were for rs17388148, an imputed proxy for rs61764370; even though rs17388148 is highly correlated with rs61764370 ($r^2 = 0.97$) and was imputed with high accuracy ($r^2 = 0.977$) [12,13]. The minor allele of rs61764370 was also associated with shorter survival time in a study of 279 ovarian cancer patients diagnosed after age 52 years with platinum-resistant disease (28 resistant, 263 not resistant) and with sub-optimal debulking surgery after neoadjuvant chemotherapy (7 sub-optimal, 109 optimal) [14]. However, another study observed no association between rs61764370 and ovarian cancer outcome (329 cases) [15].

For breast cancer, a borderline significant increased frequency of the rs61764370 G allele was observed in 268 BRCA1 mutation carriers with breast cancer, but not in 127 estrogen receptor (ER)-negative familial non-BRCA1/BRCA2 breast cancer patients [5]. However, in a subsequent study, the variant was reported to be associated with increased risk of ER/PR negative disease (80 cases, 470 controls), as well as with triple negative breast cancer diagnosed before age 52 (111 cases, 250 controls), regardless of BRCA1 mutation status [6]. The validity of these findings has been questioned given the very small sample sizes and the number of subgroups tested [16,17]. Another report found no association with sporadic or familial breast cancer risk (695 combined cases, 270 controls), but found that the variant was associated with ERBB2-positive and high grade disease, based on 153 cases who used post-menopausal hormone replacement therapy [18].

It has also been reported, based on 232 women with both primary ovarian and breast cancer, that the frequency of the G allele at rs61764370 was increased for those who were screened negative for BRCA1 and BRCA2 (92 cases), particularly among those enrolled within two years of their ovarian cancer diagnosis (to minimize survival bias, 30 cases), those diagnosed with post-menopausal ovarian cancer (63 cases), those with a family history of ovarian or breast cancer (24 cases), and those with a third primary cancer (16 cases) [4].
This notable lack of consistency in findings between studies might be expected when appropriate levels of statistical significance are not used to declare positive findings from multiple small subgroup comparisons or post-hoc hypotheses [19]. In this respect, the dangers of subgroup analyses in the context of clinical trials are well-recognized [20]. These are important caveats, particularly since a genetic test for rs61764370 is currently marketed in the US for risk prediction testing to women who are at increased risk for developing ovarian and/or breast cancer or women who have been diagnosed with either ovarian or breast cancer themselves [21]. In general, much larger studies, with sufficient power to detect positive findings at much more stringent levels of statistical significance ought to be required to establish the clinical validity of a genetic test. Therefore, we conducted centralized genotyping of rs61764370 and other variants in the genomic region around the KRAS gene in 140,012 women to examine associations with risk and clinical outcome of ovarian and breast cancer.

2. Methods

2.1. Study participants

The following three consortia contributed to these analyses: the Ovarian Cancer Association Consortium (OCAC: 41 studies, Supplementary Table S1) [22], the Breast Cancer Association Consortium (BCAC: 37 studies, Supplementary Table S2) [23], and the Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA: 55 studies, Supplementary Table S3) [24,25]. OCAC and BCAC consisted of case–control studies of unrelated women, and CIMBA consisted of studies of women with germline deleterious BRCA1 or BRCA2 mutations primarily identified through clinical genetics centers. For the purpose of the current analyses, only participants of European ancestry were included. Following genotyping, quality control exclusions (described below), and analysis-specific exclusions, data from the following women were available for analysis: 46,173 OCAC participants (15,357 patients with invasive epithelial ovarian cancer and 30,816 controls), 71,170 BCAC participants (33,530 patients with invasive breast cancer and 37,640 controls), and 22,669 CIMBA participants (for ovarian cancer analyses: 2332 affected and 12,433 unaffected BRCA1 carriers, 599 affected and 7305 unaffected BRCA2 carriers; for breast cancer analyses: 7543 affected and 7222 unaffected BRCA1 carriers, 4138 affected and 3766 unaffected BRCA2 carriers). For OCAC, overall and progression-free survival data were available for 3096 patients from 13 studies. Overall survival data were available for 28,471 patients from 26 BCAC studies and for 2623 mutation carriers with breast cancer from 11 CIMBA studies (excluding studies with less than ten deaths) as described previously [26,27]. Each study was approved by its relevant governing research ethics committee, and all study participants provided written informed consent.

2.2. Genotyping and imputation

Genotyping for rs61764370 was performed using the custom iCOGS Illumina Infinium iSelect BeadChip, as previously described [22–25]. In total, DNA from 185,443 women of varying ethnic background was genotyped (47,630 OCAC participants, 114,255 BCAC participants, 23,558 CIMBA participants), along with HapMap2 DNAs for European, African, and Asian populations. Genotype data were also available for three OCAC genome-
wide association studies (UK GWAS, US GWAS, Mayo GWAS) that had been genotyped using either the Illumina Human610-Quad Beadchip (12,607 participants) [28] or the Illumina HumanOmni2.5–8 Beadchip (883 participants). Raw intensity data files underwent centralized genotype calling and quality control [22–25]. HapMap2 samples were used to identify women with predicted European intercontinental ancestry; among these women, a set of over 37,000 unlinked markers was used to perform principal component (PC) analysis [29]. The first five and seven European PCs were found to control adequately for residual population stratification in OCAC and BCAC data, respectively. Samples with low conversion rate, extreme heterozygosity, non-female sex, or one of a first-degree relative pair (the latter for OCAC and BCAC only) were excluded. Variants were excluded if they were monomorphic or had a call rate <95% (minor allele frequency (MAF) >0.05) or <99% (MAF <0.05), deviation from Hardy–Weinberg equilibrium (p< $10^{-7}$), or >2% duplicate discordance.

In addition to rs61764370, 54 variants within 100 kb on either side of KRAS on chromosome 12 (25,258,179 to 25,503,854 bp in GRCh37.p12) were genotyped. Moreover, to provide a common set of variants across the region for analysis in all the data sets, we also used imputation to infer genotypes for another 1056 variants and for variants that failed genotyping. We performed imputation separately for OCAC samples, BCAC samples, BRCA1 mutation carriers, BRCA2 mutation carriers, and for each of the OCAC GWAS. We imputed variants from the 1000 Genomes Project data using the v3 April 2012 release as the reference panel [30]. To improve computation efficiency we initially used a two-step procedure, which involved pre-phasing using the SHAPEIT software [31] in the first step and imputation of the phased data in the second. We used the IMPUTE version 2 software [32] for the imputation for all studies with the exception of the US GWAS for which we used the MACH algorithm implemented in the minimac software version 2012.8.15 and MACH version 1.0.18 [33]. We excluded variants from association analyses if their imputation accuracy was $r^2 < 0.30$ or their MAF was <0.005, resulting in 974 variants genotyped and imputed for OCAC, 989 variants genotyped and imputed for BCAC, and 1001 variants genotyped and imputed for CIMBA, including rs61764370 (Supplementary Tables S5, S6, and S7).

### 2.3. Analysis

Genotypes were coded for genotype dosage as 0, 1, or 2, based on the number of copies of the minor allele. For ovarian cancer case–control analysis (i.e., OCAC studies), logistic regression provided estimated risks of invasive epithelial ovarian cancer with odds ratios (ORs) and 95% confidence intervals (CIs) adjusting for study, age, and the five European PCs. Subgroup analyses were conducted by histology, family ovarian and breast cancer history, menopausal status, time between ovarian cancer diagnosis and recruitment, and history of multiple primary cancers. For breast cancer case–control analysis (i.e., BCAC studies), the association between genotype and invasive breast cancer risk was evaluated by logistic regression, adjusting for study, age, and the seven European PCs, providing ORs and 95% CIs. Additional subgroup analyses were based on receptor status, first-degree family ovarian and breast cancer history, BRCA1 and BRCA2 mutation status, enrollment within two years of diagnosis, menopausal status (i.e. last menstruation longer than twelve months
ago), age at diagnosis less than 52 years, and history of hormone replacement therapy use (i.e. longer than twelve months use). Risk analysis for BRCA1 and BRCA2 mutation carriers (i.e. CIMBA studies) was done using a Cox proportional hazard model to estimate hazard ratios (HRs) per copy of the minor allele, with age as follow-up time and stratified by country of residence; US and Canadian strata were further subdivided by self-reported Ashkenazi Jewish ancestry [24,25]. A weighted cohort approach was applied to correct for potential testing bias due to overrepresentation of cases in the study population [34]. We used robust variance estimation to allow for the non-independence of carriers within the same family [35]. To assess associations with ovarian cancer risk, mutation carriers were followed from birth until ovarian cancer diagnosis (event), a risk-reducing salpingo-oophorectomy (RRSO) or the age at enrollment, whichever occurred first. We also performed analyses restricted to women diagnosed or censored within two years before their enrollment. To assess associations with breast cancer risk, mutation carriers were followed from birth until a breast cancer diagnosis (i.e. either ductal carcinoma in situ or invasive breast cancer), ovarian cancer diagnosis, a risk-reducing bilateral prophylactic mastectomy or the age at enrollment, whichever occurred first. Survival analysis of OCAC patients used Cox proportional hazards models estimating HRs and 95% CIs considering overall survival as well as progression-free survival following ovarian cancer diagnosis. Overall survival was adjusted for age at diagnosis, the five European PCs, histology, grade, FIGO stage, and residual disease after debulking surgery, and stratified by study, left truncating at the date of study entry and right censoring at five years to minimize events due to other causes. Progression-free survival was analyzed as for overall survival, but without adjustment for age and right censoring, and was defined as the time between the date of histologic diagnosis and the first confirmed sign of disease recurrence or progression, based on GCIG (Gynecological Cancer InterGroup) criteria [36]. We also performed subgroup analysis of patients suboptimally debulked after cytoreductive surgery (residual disease >1 cm) and of post-menopausal patients (age at diagnosis >52 years). Survival analysis of BCAC patients used Cox proportional hazard models estimating HRs and 95% CIs considering overall and breast cancer-specific survival following breast cancer diagnosis. Models were adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and stratified by study, left-truncating at the date of study entry and right censoring at ten years. In addition, we performed subgroup analysis on ER-positive and ER-negative patients. For CIMBA breast cancer patients associations between genotype and overall survival were evaluated using Cox proportional hazard models estimating HRs and 95% CIs. Models were adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and stratified by study, left-truncating at the date of study entry and right censoring at twenty years. Analyses were performed using STATA version 12.0 (StataCorp, Texas, USA).

3. Results

The results of the overall analysis as well as the subgroup analyses investigating the association between the minor allele at rs61764370 and ovarian cancer risk, breast cancer risk, and ovarian and breast cancer risks in BRCA1 and BRCA2 mutation carriers are shown.
in Table 1. Associations with clinical outcomes in and ovarian and breast cancer patients including \textit{BRCA1} and \textit{BRCA2} mutation carriers are shown in Table 2 and Supplementary Table S4.

We found no evidence for association between the rs61764370 G allele and ovarian or breast cancer risk. The most statistically significant association was observed for risk of low-grade serous ovarian cancer (n = 485; OR 0.76, 95% CI 0.59–0.97, p = 0.031), but this finding was not significant after Bonferroni correction for multiple testing. We also evaluated the association for additional specific subgroups in which an association with rs61764370 had been reported previously [3–6]. Ovarian cancer subgroups considered \textit{BRCA1} mutation carriers as well as \textit{BRCA1} and \textit{BRCA2} screened-negative patients with first degree family histories of breast or ovarian cancer and patients who had been diagnosed with breast cancer before their ovarian cancer diagnoses. For breast cancer these included, among others, \textit{BRCA1} mutation carriers, patients diagnosed with ER- and PR-negative tumors, and patients diagnosed with triple negative tumors before age 52 years. Importantly, we observed no evidence for association of rs61764370 with any of these subgroups (detailed in Table 1), with all ORs close to unity and very narrow CIs including unity.

Similarly, case-only analyses did not reveal any associations between rs61764370 genotype and ovarian and breast cancer clinical features or outcome (Table 2 and Supplementary Table S4). For example, the previously reported association between rs61764370 and risk of \textit{ERBB2}-positive and high grade breast cancer in hormone replacement therapy users [18] was not replicated (Supplementary Table S4), and in ovarian cancer analyses we found no evidence of reduced survival among patients diagnosed after age 52 years or patients with suboptimal debulking after cytoreductive surgery (Table 2) [14]. The G allele of rs61764370 was also not associated with survival of breast cancer patients (Table 2).

Finally, we evaluated the association between the primary phenotypes of interest and common genetic variation (MAF > 0.02) in the genomic region of \textit{KRAS} (i.e., within 100 kb on either side of the gene), using imputed and genotyped data on 974 variants for OCAC, 989 variants for BCAC, and 1001 variants genotyped and imputed for CIMBA (Supplementary Tables S5, S6, and S7). We found no evidence of association for any of these variants, including rs61764370 and rs17388148, with these phenotypes that would withstand Bonferroni correction for multiple testing, as detailed in Supplementary Tables S5, S6, and S7 and shown in regional association plots (Fig. 1).

4. Discussion

Our analysis of 140,012 women genotyped for inherited variants in the \textit{KRAS} region provides definitive clarification of the role of these variants in ovarian and breast cancer susceptibility and outcome. We have found no evidence to support an association between rs61764370 and ovarian or breast cancer risk, or clinical outcomes in patients with ovarian or breast cancer. In the absence of any association and with ORs close to unity we would not typically consider sub-group analyses, particularly sub-groups for which differential associations would not be expected to occur. However, given the previous positive associations reported for a myriad of different subgroups, we tested for association among
each of these subgroups and found no evidence to support the previously reported associations.

Our study has notable strengths. The vast majority (i.e. >95%) of the samples were genotyped using the same genotyping platform and employing a common approach to genotype calling and quality control; additional samples used denser arrays and nearly identical procedures. The very large sample sizes for all the major phenotypes of interest provide substantial statistical power to exclude any clinically relevant associated risks for the major phenotypes of interest (Fig. 2). The null results found here are thus not due to lack of statistical power, and this analysis also had greater than 80% power to detect association for most of the subgroups, although for some subgroups it was not possible to exclude modest risks. In contrast to the current findings, other genetic association analyses using the same genotyping platform and the same studies as included here have identified more than 90 common germline variants associated with ovarian or breast cancer risk at \( p < 5 \times 10^{-8} \) [22,23,37]. While critiques on a previous null KRAS report have suggested that inclusion of male controls, use of “prevalent” cases, and reliance on a surrogate genetic variant may have led to falsely negative conclusions, these are not issues in the present data set. Rather, we demonstrate the importance of international collaboration to identify true associations as well as to refute false associations, an equally important objective.

The rise of individualized medicine including the use of panels of common variants to predict cancer risk more accurately than using family history alone holds great promise [38]. For example, the 31 prostate cancer susceptibility alleles confirmed as of 2011 (at \( p < 5 \times 10^{-8} \)) can be combined to identify men in the top one percent of the risk distribution having a 3.2-fold increased risk [39]. Prediction has since then improved with now over 70 prostate cancer susceptibility alleles [40] and the utility of these genetic tests is currently under clinical evaluation. A similar clinical examination in ovarian and breast cancer is not far behind, with now over 18 and 77 confirmed susceptibility alleles, respectively, for these cancers [22,23]. The genotype at rs61764370, however, does not predict ovarian or breast cancer risk, even among particular subgroups of women or for particular subtypes of disease, nor is it a marker of differential outcome following diagnosis with these cancers. Therefore, genetic test results for rs61764370 should not be used to counsel women about their ovarian or breast cancer risks or outcome. Our results highlight the dangers of developing clinical tests without appropriate data from carefully conducted, large-scale studies to establish clinical validity.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Authors**

Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Antoinette Hollestelle\(^a,1\), Frederieke H. van der Baan\(^b,1\), Andrew Berchuck\(^c,1\)*, Sharon E. Johnatty\(^d\), Katja K. Aben\(^e,f\), Bjarni A. Aagnarsson\(^g,ix\), Kristiina Aittomäki\(^h\), Elisa Alducci\(^i\), Irene L.
Argyrios Ziogas, Georgia Chenevix-Trench, Paul D.P. Pharoah, Matti A. Rookus, Maartje J. Hooning, and Ellen L. Goode

**Affiliations**

aDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands 
bDepartment of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands 
cDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA 
dDepartment of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia 
eComprehensive Cancer Center The Netherlands, Utrecht, The Netherlands 
fDepartment for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands 
gLandspitali University Hospital, Reykjavik, Iceland 
hDepartment of Clinical Genetics, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland 
iImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy 
jen Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada 
kOntario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Lumenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada 
lDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany 
mDepartment of Gynecology and Obstetrics, University Hospital of Schleswig-Holstein, University Kiel, Germany 
nBreakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK 
oco Cancer Division, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia 
doDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden 
eDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia 
fxWestern Sydney and Nepean Blue Mountains Local Health Districts, Westmead Millennium Institute for Medical Research, University of Sydney, Sydney, Australia 
fRutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA 
gDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA 
hKnight Cancer Institute, Oregon Health and Science University, Portland, OR, USA 
iInstitute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany 
jaUniversity Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
et al. Gynecol Oncol. Author manuscript; available in PMC 2017 May 01.
Department of Oncology, The University of Melbourne, Australia
Department of Pathology, University of Melbourne, Melbourne, VIC, Australia
Gynaecological Oncology, The Chris O'Brien Lifehouse and The University of Sydney, Sydney, Australia
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Center for Medical Genetics, Ghent University, Ghent, Belgium
Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands
Division of Epidemiology and Biostatistics, University of New Mexico, Albuquerque, NM, USA
Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA
Department of Laboratory Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN, USA
Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, UK
Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA
Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK
International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical Academy, Szczecin, Poland
INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France
Molecular Oncology Laboratory, Hospital Clínic de Barcelona, Spain
Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
Oncogenetics Laboratory, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Section of Biostatistics and Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Basser Research Centre, Abramson Cancer Center, The University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA
Department of Genetics, University of Pretoria, Pretoria, South Africa
Non-Communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London, UK
Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Klinik Wiesbaden, Wiesbaden, Germany
Department of Gynecology and Gynecologic Oncology, Klinikum Essen-Mitte, Essen, Germany
Centre Hospitalier Universitaire de Québec Research Center, Laval University, Quebec, Canada
Institute of Biology and Molecular Genetics, Universidad de Valladolid (IBGM-UVA), Valladolid, Spain
Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK
Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Department of Clinical Genetics, Lund University, Lund, Sweden
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Institute of Human Genetics, Friedrich Alexander Universität, Erlangen-Nürnberg, Germany

Gynecol Oncol. Author manuscript; available in PMC 2017 May 01.
University Erlangen-Nuremberg, Erlangen, Germany c Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany c David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, CA, USA d Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain d Department of Cancer Epidemiology/Clinical Cancer Registry, Institute for Medical Biometrics and Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg, Germany d Clinical Cancer Genetics, City of Hope, Duarte, CA, USA d New Mexico Cancer Center, Albuquerque, NM, USA d Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy d Cogentech Cancer Genetic Test Laboratory, Milan, Italy d Molecular Diagnostics Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Centre for Scientific Research Demokritos, Aghia Paraskevi Attikis, Athens, Greece d Kansas IDeA Network of Biomedical Research Excellence Bioinformatics Core, The University of Kansas Cancer Center, Kansas City, KS, USA d University of Pennsylvania, Philadelphia, PA, USA d The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel-Hashomer, Israel d Institute of Oncology, Sheba Medical Center, Tel-Hashomer, Israel d Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA d Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA d Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA d GEMO Study: National Cancer Genetics Network, UNICANCER Genetic Group, France d Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany d Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany d Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany d Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany d Gynaeological Cancer Research Centre, Department of Women's Cancer, Institute for Women's Health, UCL, London, UK d Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark d Cancer Research UK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Glasgow, UK d Ontario Cancer Genetics Network, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada d Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA d Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA d Gynecological Oncology Unit, The Royal Marsden Hospital, London, UK d Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA d Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland d Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland d INSERM U1018, CESP (Center for Research in Epidemiology and Population Health), Environmental Epidemiology of Cancer, Villejuif, France d University Paris-Sud, UMRS 1018, Villejuif, France d Division of Epidemiology,
Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium fnLeuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium fnDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA foGenetic and Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain gpUniversité Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France fqCancer Control Research, BC Cancer Agency, Vancouver, BC, Canada frCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA fsCollege of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA ftDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden fuCenter for Individualized Medicine, Mayo Clinic, Scottsdale, AZ, USA fvDepartment of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland gwDepartment of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA gxDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden gyNational Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany fzDepartment of Gynecology, Radboud University Medical Centre, Nijmegen, The Netherlands gaLaboratoire de Diagnostic Génétique et Service d’Onco-hématologie, Hopitaux Universitaires de Strasbourg, CHRU Nouvel Hôpital Civil, Strasbourg, France gbDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA gcAnatomical Pathology, The Alfred Hospital, Melbourne, Australia gdInstitute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, UK geDepartment of Gynecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich, Munich, Germany gfServicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain ggDepartment of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland ghDepartment of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands giWomen’s Cancer Research Program, Magee-Women’s Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA gjDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada gkLaboratory Medicine Program, University Health Network, Toronto, ON, Canada glWomen’s College Research Institute, University of Toronto, Toronto, ON, Canada gmThe University of Texas School of Public Health, Houston, TX, USA gnDepartment of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA goDepartment of Medicine and Institute for Human Genetics, University of California, San Francisco, CA, USA gpClinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA gqDepartment of Molecular Genetics, National Institute of Oncology, Budapest, Hungary grCenter for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, IL, USA gsDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA gtUniversity of Groningen, University Medical
Center, Department of Genetics, Groningen, The Netherlands 
Department of Molecular Medicine, Sapienza University, Rome, Italy 
Section of Molecular Diagnostics, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark 
Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori (INT), Milan, Italy 
Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA 
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia 
Department of Medicine, St Vincent's Hospital, The University of Melbourne, Victoria, Australia 
NRG Oncology Statistics and Data Management Center, Buffalo, NY, USA 
Channing Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA 
Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Genetics, University of Oulu, Oulu University Hospital, Oulu, Finland 
Biocenter Oulu, University of Oulu, Oulu, Finland 
Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori (INT), Milan, Italy 
Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 
Clalit National Israeli Cancer Control Center, Haifa, Israel 
Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Haifa, Israel 
Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA 
NorthShore University Health System, University of Chicago, Evanston, IL, USA 
Department of Epidemiology, University of Washington, Seattle, WA, USA 
Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 
Department of Gynecology, Jena University Hospital, Jena, Germany 
Ohio State University, Columbus, OH, USA 
Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, London, UK 
Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA 
Cancer Prevention, Detection and Control Research Program, Duke Cancer Institute, Durham, NC, USA 
Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics, University Hospital of Cologne, Cologne, Germany 
Centre for Molecular Medicine Cologne (CMMC), University Hospital of Cologne, Cologne, Germany 
Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey, UK 
Institut für Humangenetik Wiesbaden, Wiesbaden, Germany 
Department of Gynecological Oncology, Glasgow Royal Infirmary, Glasgow, UK 
Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon, Centre Léon Bérard, Lyon, France 
Department of Clinical Genetics, University and Regional Laboratories, Lund University Hospital, Lund, Sweden 
Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, Australia 
Saarland Cancer Registry, Saarbrücken, Germany 
Institut Curie, Department of Tumour Biology, Paris, France

Gynecol Oncol. Author manuscript; available in PMC 2017 May 01.
Acknowledgments

We thank all the individuals who took part in this study and all the researchers, clinicians and administrative staff who have made possible the many studies contributing to this work.

The COGS project is funded through a European Commission’s Seventh Framework Programme grant (agreement number 223175 -HEALTH-F2-2009-223175). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk/. Funding for the project was provided by the Wellcome Trust under award 076113.

G.C.-T. and P.M.W. are supported by the National Health and Medical Research Council; P.A.F. is supported by the Deutsche Krebshilfe; B.K. holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN); K.-A.P. is an Australian National Breast Cancer Foundation Fellow; and A.B. holds the Barbara Thomason Ovarian Cancer Research Professorship from the American Cancer Society (SIOP-06-090-06). R. Balleine was a Cancer Institute NSW Clinical Research Fellow.

OCAC, in particular, acknowledges D. Bowtell, A. deFazio, D. Gertig, A. Green, P. Parsons, N. Hayward and D. Whiteman (AUS); G. Peuteman, T. Van Brussel and D. Smeets (BEL); U. Eilber and T. Koehler (GER); L. Gacucova (HMO); P. Schirrmann, F. Kramer, W. Zheng, T.-W. Park-Simon, K. Beer-Grondke and D. Schmidt.
et al. Page 18

(CIMBA) studies also acknowledge the following. BCFR: This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Institutes of Health. CONSIT TEAM: Italian Association for Cancer Research (AIRC) and funds from Italian citizens who allocated the 5 × 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects ‘5 × 1000’). CORE: The CIMBA data management and data analysis were supported by Cancer Research — UK grants C12292/A11174 and C1287/A10118. SH is supported by an NHMRC Program Grant of GCT. ACA is a Cancer Research — UK Senior Cancer Research Fellow. GCT is an NHMRC Senior Principal Research Fellow. DEMOKRITOS: This research has been co-financed by European Social Fund (ESF) and Greek national funds through the Operational Program “Education and Gynecol Oncol. Author manuscript; available in PMC 2017 May 01.
et al. Page 19


FCCC: The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program. A.K.G. was funded by SU01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences Professorship. We thank Ms. JoEllen Weaver and Dr. Betsy Bove for their technical support. GC-HBOC: The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 109076, Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC). GEMO: The study was supported by the Ligue Nationale contre le Cancer; the Association “Le cancer du sein, parlons-en!” Award; and the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program. Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: National Cancer Genetics Network “UNICANCER Genetic Group”, France. We wish to thank all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are: Coordinating Centres, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon: Jean Leo Béraud, & Equipe “Génétique du cancer du sein”, Centre de Recherche en Cancérologie de Lyon: Olga Sinilnikova, Sylvie Mazoyer, Francesca Damiolo, Laura Batjhoux, Carole Vernet-Pierre, Alain Calender, Sophie Giraud, Mélanie Léone; and Service de Génétique Oncohématologie, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gautheir-Villas, Bruno Buecher, Claude Houdayer, Virginie Moncoullet, Muriel Belotti, Carole Tirapo, Antoine de Pauw, Institut Gustave Roussy, Villejuif: Brigitte Bressac-de-Paillerets, Olivier Caron. Centre Benoît Perrin, Clermont–Ferrand: Yves-Jean Bignon, Nancy Uthhammer. Centre Léon Bérard, Lyon: Christine Lassett, Valérie Bonadora, Sandrine Handallou. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Berthet. Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, Audrey Remeniers, Françoise Eisinger. CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupiet, Stéphane Josso, Guillaume Babinet. Centre de Léon Blum, Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillon, Philippe Vennin, Claude Adenis. Hôpital René Huguenin/Institut Curie, St Cloud: Etienne Rouleau, Rosette Lidereau, Liliane Demange, Catherine Nogues. Centre Pierreaussier, Strasbourg: Danielle Muller, Jean-Pierre Fricker. Institut Bergonié, Bordeaux: Emmanuelle Barouar-Simonet, Françoise Bonnet, Virginie Bubien, Nicolas Sevenet, Michel Longy. Institut Claudius Regaud, Toulouse: Christine Touslas, Rosine Guimbaud, Laurence Gladieff, Viviane Feillel. CHU Grenoble: Dominique Leroux, Hélène Dreyfus, Christine Rebischung, Magalie Peysselon. CHU Dijon: Fanny Coron, Laurence Faivre. CHU St-Etienne: Fabienne Priue, Marine Lebrun, Caroline Kientz. Hôtel Dieu Centre Hospitalier, Chambéry: Sandra Ferr Ferret. Centre Antoine Lacassagne, Nice: Marc Fréay, CHU Limoges: Laurence Venat-Bouvet. CHU Nantes: Capucine Delattre. CHU Bretonneau: Tours: Isabelle Mortemousque, Groupe Hospitalier Pitie-Salpêtrière, Paris: Florence Coulot, Chloé-Elise Colas, Florent Soubrier. CHU Vandoeuvre-les-Nancy: Johanna Sokolowska, Myriam Bronner. CHU Besançon: Marie-Agnès
Human Genetics Sample Bank. PBCS: This work was supported by the ITT (Istituto Toscano Tumori) grants 2011–2013. SMC: This project was partially funded through a grant by the Israel cancer association and the funding for the Israeli Inherited breast cancer consortium. SMC team wishes to acknowledge the assistance of the Meirav Cancer Comprehensive breast cancer center team at the Sheba Medical Center for assistance in this study. SWE-BRCA: SWE-BRCA collaborators are supported by the Swedish Cancer Society. Swedish scientists participating as SWE-BRCA collaborators are: from Lund University and University Hospital: Åke Borg, Håkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; from Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; from Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantalä; from Umeå University Hospital: Beatrice Melin, Christina Edwindsdotter Ardnor, Monica Emanuelsson; from Uppsala University: Hans Ehrencrona, Maritta Hellström Pigg, Richard Rosenquist; and from Linköping University Hospital: Marie Stenmark-Askmael, Signur Liedgren.

UCHICAGO: UCHICAGO is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, U01 CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women’s Cancer Research Alliance and the Breast Cancer research Foundation. OIO is an ACS Clinical Research Professor. We wish to thank Cecilia Zvocec, Qun Niu, physicians, genetic counselors, research nurses and staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to our program. UCLA: Patricia Ganz and the Jonsson Comprehensive Cancer Center Foundation; Breast Cancer Research Foundation. We thank Joyce Seldon MSGC and Loma Kwan, MPH for assembling the data for this study. UCSF: UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center. We would like to thank Dr. Robert Nussbaum and the following genetic counselors for participant recruitment: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco and Peggy Conrad. And thanks to Ms. Salina Chan for her data management. UKFOCR: UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We thank Carole Pope, Patricia Harrington and Eva Wozniak for their contributions towards the UKFOCR. UPENN: National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855); Breast Cancer Research Foundation; Rooney Family Foundation; Susan G. Komen Foundation for the Cure, Bassler Research Center for BRCA. VFCGT: Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation. Geoffrey Lindeman, Marion Harris, and Martin Delatycki of the Victorian Familial Cancer Trials Group. We thank Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification. WCP: The Women’s Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer Institute is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN).

BCAC studies also acknowledge the following. We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out. Part of this work was supported by the European Community’s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). This work was partly supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program (J.S. & D.E.), and the Ministry of Economic Development, Innovation and Export Trade of Quebec — grant # PSR-SIIIRI-701 (J.S. & D.E., P. Hall). The BCAC is funded by CR-UK (C1287/A10118 and C1287/A12014). Meetings of the BCAC have been funded by the European Union COST program (BM0606). D.E. is a Principal Research Fellow of CR-UK. J.S. is chair holder of the Canada Research Chair in Oncogenetics. ABCFS: Maggie Angelakos, Judi Maskiell, and Gillian Dite. The ABCFS, NC-BCFR and OFBCR work was supported by the United States National Cancer Institute, National Institutes of Health (NIH) under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Northern California Cancer Center (U01 CA69417), and University of Melbourne (U01 CA69638). Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names and commercial products, or organizations imply endorsement by the US Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. M.C.S. is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. The ABCS study was supported by the Dutch Cancer Society [grants NKI 307-3859; 2009 4363]; BBMRI-NL, which is a Research Infrastructure financed by the Dutch government (NWO 184.021.007); and the Dutch National Genomics Initiative. BBCC: The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. BBCS: Eileen Williams, Elaine Ryder-Mills, Kara Sargus. The BBCS is funded by Cancer Research UK and Breakthrough Breast Cancer and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). BIGGS: ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. Niall McInerney, Gabrielle Colleran, Andrew Rowan, Angela Jones. BSUCH: The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center. DTFZ: CECILE Medical Faculty Mannheim. CECILE: This study was funded by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Ligue contre le Cancer.
et al. Gynecol Oncol. Author manuscript; available in PMC 2017 May 01.

Grand Ouest, Agence Nationale de Sécurité Sanitaire (ANSES), and Agence Nationale de la Recherche (ANR).

CNIO-BCS: The CNIO-BCS was supported by the Genome Spain Foundation, the Red Tematica de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (P11/00923 and P1081120). The Human Genotyping-CEGEN Unit (CNIO) is supported by the Instituto de Salud Carlos III. Guillermo Pita, Charo Alonso, Daniel Herrero, Nuria Álvarez, Pilar Zamora, Primitiva Menendez, the Human Genotyping-CEGEN Unit (CNIO). CTS: The CTS was supported by the California Breast Cancer Act of 1993; National Institutes of Health (grants R01 CA77398 and the Lon V Smith Foundation [LV53942]); and the California Breast Cancer Research Fund (contract 97-10500). Collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. ESTHER: The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDII study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). Hartwig Ziegler, Sonja Wolf, Volker Hermann. GENICA: The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KWK977/5, 01KWK976/8, 01KWK977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GENICA Network: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen, Germany; [H.B., Wing-Yee Lo, Christina Justenhoven], Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany [Yon-Dschun Ko, Christian Baisch], Institute of Pathology, University of Bonn, Bonn, Germany [Hans-Peter Fischer], Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany [U.H.], Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany [T.B., Beate Pesch, Sylvia Rabstein, Anne Spickenhuefer], Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany [Volker Harth]. HEBCS: The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, The Nordic Cancer Union and the Sigrid Juselius Foundation. Karl von Smitten, Tuomas Heikkinen, Dario Greco, Iria Eikliêla. HBBCS: The HBBCS was supported by a grant from the Friends of Hannover Medical School and by the Rudolf Bartling Foundation. Peter Hillemanns, Hans Christiansen and Johann H. Karstens. HUBCS: The HUBCS was supported by a grant from the German Federal Ministry of Research and Education (RUS08/017). KARBAC: The KARBAC study was supported by the Swedish Cancer Society, the Gustav V Jubilee Foundation and the Bert von Kantzow foundation. KBPC: The KBPC was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, the Academy of Finland and by the strategic funding of the University of Eastern Finland. Eija Myöhänen, Helena Kemiläinen. kConFab/AOCS: kConFab is supported by grants from the National Breast Cancer Foundation, the NHMRC, the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia and the Cancer Foundation of Western Australia. The kConFab Clinical Follow Up Study was funded by the NHMRC[145684, 288704, 454508]. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia [NHMRC; 400413, 400281,199600]. G.C.T. and P.W. are supported by the NHMRC. Heather Thorne, Eveline Niedermayr, the AOCs Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green, P Webb), the ACS Management Group (A Green, P Parsons, N Hayward, P Webb, D Whitehan). LMB/C: LMB/C is supported by the ‘Stichting tegen Kanker’ (232-2008 and 196-2010). Diether Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII. Gilian Peuteman, Dominiek Smeets, Thomas Van Brussel and Kathleen Corthouts. MARIE: The MARIE study was supported by the Deutsche Krebshilfe e.V [70-2892-BR I], the Hamburg Cancer Society, the German Cancer Research Center and the genotype work in part by the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. Tracy Slanger, Elke Mutschelknauss, Ramona Salazar, S. Behrens, R. Birr, W. Busch, U. Eilber, B. Kaspereit, N. Knese, K. Smit. MBCSG: MBCSG was funded by grants from the Italian Association for Cancer Research (AIRC) and thanks Siranoush Manoukian of the Istituto Nazionale dei Tumori, Milano, Italy; Monica Barile and Irene Feroce of the Istituto Eutopeo di Oncologia, Milan, Italy; Giuseppe Giannini of the Sapienza University, Rome, Italy; Loris Bernard end per personnel of the Cogentech Genetic Test Laboratory, Milan, Italy. MCBCS: The MCBCS was supported by the NIH grants [CA122340, CA128978], an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116211], the Breast Cancer Research Foundation, and the Komen Race for the Cure. MCCS: MCCS cohort recruitment in the study was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. MEC: The MEC was supported by NIH grants CA63464, CA54281, CA098758 and CA132839. MTLEGBCS: The authors gratefully acknowledge Martine Tranchant for DNA extraction, sample management and skilful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics. The work of MTLEGBCS was supported by the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program — grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade — grant # PSR-SIBRI-701. NBCS: The NBCS was supported by grants from the Norwegian Research council, 155218/V30, 175240/S10 to ALBD, FUGE-NFR 181600/V11 to VNK and a Swizz Bridge Award to ALBD. NBHS: The NBHS was supported
References


Fig. 1.
Regional association plots for variants within the genomic region 100 kb either side of KRAS and risk of ovarian and breast cancer. X-axis position is referent to position (bp) on chromosome 12, build GRCh37.p12; yellow line indicates position of KRAS; red triangle indicates rs61764370. Y-axis is $-\log_{10}(p$-values) from association tests for risk of A) ER-negative breast cancer, B) ER-positive breast cancer, C) breast cancer in BRCA1 mutation carriers, D) breast cancer in BRCA2 mutation carriers, E) epithelial ovarian cancer, F) epithelial ovarian cancer in BRCA1 mutation carriers, and G) epithelial ovarian cancer in BRCA2 mutation carriers.
BRCA2 mutation carriers. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 2.
Power curve for modest risk variants according to the total sample size. X-axis is total sample size for which case–control ratio is 1:1. Y-axis is the statistical power (range 0.5–1.0) for variants given a range of risks, assuming alpha = 0.01 and minor allele frequency 0.09.
Table 1
Associations between \textit{KRAS} rs61764370 and risk of ovarian and breast cancer

For \textit{BRCA1} and \textit{BRCA2} mutation carrier analyses, cases are affected \textit{BRCA1/BRCA2} mutation carriers and controls are unaffected \textit{BRCA1/BRCA2} mutation carriers, and relative risks are estimated by hazard ratios; for other analyses, relative risks are estimated by odds ratios; ovarian cancer analyses used OCAC data adjusted for study, age, and the five European principal components; breast cancer analyses used BCAC data adjusted for study, age, and the seven European principal components; \textit{BRCA1} and \textit{BRCA2} mutation carrier analyses used CIMBA data with age as follow-up time and stratified for country; 95% CI, 95% confidence interval.

<table>
<thead>
<tr>
<th></th>
<th>Number</th>
<th>Minor allele frequency</th>
<th>Relative risk (95% CI)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases</td>
<td>Controls</td>
<td>Cases</td>
<td>Controls</td>
</tr>
<tr>
<td>All invasive</td>
<td>15,357</td>
<td>30,816</td>
<td>0.0914</td>
<td>0.0949</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-grade serous</td>
<td>6938</td>
<td>30,816</td>
<td>0.0946</td>
<td>0.0949</td>
</tr>
<tr>
<td>Endometrioid</td>
<td>2151</td>
<td>30,816</td>
<td>0.0834</td>
<td>0.0949</td>
</tr>
<tr>
<td>Clear cell</td>
<td>1015</td>
<td>30,816</td>
<td>0.0994</td>
<td>0.0949</td>
</tr>
<tr>
<td>Mucinous</td>
<td>1000</td>
<td>30,816</td>
<td>0.0902</td>
<td>0.0949</td>
</tr>
<tr>
<td>Low-grade serous</td>
<td>485</td>
<td>30,816</td>
<td>0.0705</td>
<td>0.0949</td>
</tr>
<tr>
<td>First-degree family history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>483</td>
<td>342</td>
<td>0.0803</td>
<td>0.0849</td>
</tr>
<tr>
<td>Breast or ovarian cancer</td>
<td>477</td>
<td>18,442</td>
<td>0.0977</td>
<td>0.0915</td>
</tr>
<tr>
<td>\textit{BRCA1/2} mutation negative</td>
<td>346</td>
<td>15,492</td>
<td>0.1050</td>
<td>0.0997</td>
</tr>
<tr>
<td>\textit{BRCA1} mutation carriers</td>
<td>2332</td>
<td>12,433</td>
<td>0.0954</td>
<td>0.0922</td>
</tr>
<tr>
<td>\textit{BRCA2} mutation carriers</td>
<td>599</td>
<td>7305</td>
<td>0.0952</td>
<td>0.0966</td>
</tr>
<tr>
<td>Enrolled within two years of diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All invasive</td>
<td>10,121</td>
<td>30,815</td>
<td>0.0942</td>
<td>0.0949</td>
</tr>
<tr>
<td>\textit{BRCA1} mutation carriers</td>
<td>1095</td>
<td>10,802</td>
<td>0.0950</td>
<td>0.0940</td>
</tr>
<tr>
<td>\textit{BRCA2} mutation carriers</td>
<td>270</td>
<td>6509</td>
<td>0.0907</td>
<td>0.0979</td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre- or peri-menopausal</td>
<td>4264</td>
<td>8789</td>
<td>0.0915</td>
<td>0.0927</td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>11,058</td>
<td>15,903</td>
<td>0.0916</td>
<td>0.0951</td>
</tr>
<tr>
<td>Prior breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enrolled within two years of diagnosis</td>
<td>Number</td>
<td>Minor allele frequency</td>
<td>Relative risk (95% CI)</td>
<td>p-Value</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>--------</td>
<td>------------------------</td>
<td>------------------------</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td>Cases</td>
<td>Controls</td>
<td>Cases</td>
<td>Controls</td>
</tr>
<tr>
<td>Enrolled within two years of diagnosis</td>
<td>426</td>
<td>30,815</td>
<td>0.0943</td>
<td>0.0949</td>
</tr>
<tr>
<td>Post-menopausal ovarian cancer</td>
<td>341</td>
<td>15,903</td>
<td>0.0810</td>
<td>0.0951</td>
</tr>
<tr>
<td>First degree breast or ovarian cancer family history</td>
<td>202</td>
<td>30,815</td>
<td>0.0916</td>
<td>0.0949</td>
</tr>
<tr>
<td><strong>Breast cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All invasive</td>
<td>33,530</td>
<td>37,640</td>
<td>0.0904</td>
<td>0.0930</td>
</tr>
<tr>
<td>Receptor status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER—/PR—</td>
<td>4009</td>
<td>37,043</td>
<td>0.0940</td>
<td>0.0932</td>
</tr>
<tr>
<td>ER—/PR—/ERBB2—</td>
<td>1673</td>
<td>28,480</td>
<td>0.0885</td>
<td>0.0947</td>
</tr>
<tr>
<td>First-degree family history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>4357</td>
<td>1943</td>
<td>0.0942</td>
<td>0.0954</td>
</tr>
<tr>
<td>Ovarian or breast cancer</td>
<td>4593</td>
<td>2265</td>
<td>0.0933</td>
<td>0.0949</td>
</tr>
<tr>
<td>Age diagnosis &lt;52</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER—/PR—</td>
<td>1530</td>
<td>37,043</td>
<td>0.0980</td>
<td>0.0932</td>
</tr>
<tr>
<td>ER—/PR—/ERBB2—</td>
<td>546</td>
<td>27,690</td>
<td>0.0908</td>
<td>0.0948</td>
</tr>
<tr>
<td>BRCA1/2 mutation negative</td>
<td>1431</td>
<td>1097</td>
<td>0.0853</td>
<td>0.0925</td>
</tr>
<tr>
<td>BRCA1 mutation carriers</td>
<td>7543</td>
<td>7222</td>
<td>0.0935</td>
<td>0.0919</td>
</tr>
<tr>
<td>BRCA2 mutation carriers</td>
<td>4138</td>
<td>3766</td>
<td>0.1005</td>
<td>0.0921</td>
</tr>
<tr>
<td>Enrolled within two years of diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All invasive</td>
<td>20,444</td>
<td>34,349</td>
<td>0.0924</td>
<td>0.0934</td>
</tr>
<tr>
<td>BRCA1 mutation carriers</td>
<td>2595</td>
<td>5976</td>
<td>0.0896</td>
<td>0.0924</td>
</tr>
<tr>
<td>BRCA2 mutation carriers</td>
<td>1359</td>
<td>3365</td>
<td>0.0960</td>
<td>0.0926</td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre- or peri-menopausal</td>
<td>7086</td>
<td>8642</td>
<td>0.0934</td>
<td>0.0933</td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>16,346</td>
<td>18,605</td>
<td>0.0904</td>
<td>0.0943</td>
</tr>
</tbody>
</table>
Table 2
Associations between KRAS rs61764370 and outcome in ovarian and breast cancer

Ovarian cancer analyses used OCAC data adjusted for age at diagnosis (overall survival only), the five European principal components, histology (serous, mucinous, endometrioid, clear cell, and other epithelial), grade (low versus high), FIGO stage (I–IV), residual disease after debulking surgery (nil versus any), and stratified by study; breast cancer analyses used BCAC data adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy and was stratified by study; analyses for BRCA1 and BRCA2 mutation carriers used CIMBA data adjusted for age at diagnosis, tumor size, nodal status, grade, adjuvant hormonal and/or chemotherapy, and preventive bilateral oophorectomy and was stratified by study; 95% CI, 95% confidence interval.

<table>
<thead>
<tr>
<th></th>
<th>No. of patients</th>
<th>No. of events</th>
<th>Hazard ratio (95% CI)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall survival</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>3096</td>
<td>1421</td>
<td>0.94 (0.83–1.07)</td>
<td>0.38</td>
</tr>
<tr>
<td>Patients who were suboptimally debulked after cytoreductive surgery</td>
<td>1114</td>
<td>784</td>
<td>0.94 (0.78–1.13)</td>
<td>0.50</td>
</tr>
<tr>
<td>Post-menopausal patients &gt; 52 years</td>
<td>2226</td>
<td>1276</td>
<td>0.97 (0.84–1.12)</td>
<td>0.70</td>
</tr>
<tr>
<td><strong>Progression-free survival</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>3096</td>
<td>2144</td>
<td>1.01 (0.90–1.13)</td>
<td>0.84</td>
</tr>
<tr>
<td>Patients who were suboptimally debulked after cytoreductive surgery</td>
<td>1114</td>
<td>961</td>
<td>1.03 (0.87–1.21)</td>
<td>0.74</td>
</tr>
<tr>
<td>Post-menopausal patients &gt;52 years</td>
<td>2226</td>
<td>1603</td>
<td>1.02 (0.90–1.16)</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>Breast cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Overall survival</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>28,471</td>
<td>3013</td>
<td>0.96 (0.87–1.06)</td>
<td>0.38</td>
</tr>
<tr>
<td>ER-positive patients</td>
<td>20,071</td>
<td>1754</td>
<td>0.96 (0.85–1.10)</td>
<td>0.58</td>
</tr>
<tr>
<td>ER-negative patients</td>
<td>4778</td>
<td>771</td>
<td>0.97 (0.81–1.18)</td>
<td>0.78</td>
</tr>
<tr>
<td><strong>Breast cancer-specific survival</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>28,471</td>
<td>1693</td>
<td>0.95 (0.83–1.08)</td>
<td>0.40</td>
</tr>
<tr>
<td><strong>Overall survival</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRCA1 mutation carriers</td>
<td>1706</td>
<td>241</td>
<td>0.72 (0.48–1.08)</td>
<td>0.11</td>
</tr>
<tr>
<td>BRCA2 mutation carriers</td>
<td>917</td>
<td>162</td>
<td>0.98 (0.65–1.46)</td>
<td>0.90</td>
</tr>
</tbody>
</table>